The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $47.91

Today's change+1.33 +2.86%
Updated February 10 4:02 PM EST. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $47.91

Today's change+1.33 +2.86%
Updated February 10 4:02 PM EST. Delayed by at least 15 minutes.

Novo Nordisk A/S up sharply

Novo Nordisk A/S closed up sharply Wednesday, rallying (U.S.)$1.33 or 2.86% to (U.S.)$47.91. Over the last five days, shares have lost 7.33% and are down 17.51% for the last year to date. This security has outperformed the S&P 500 by 22.42% during the last year.

Key company metrics

  • Open(U.S.) $48.55
  • Previous close(U.S.) $46.58
  • High(U.S.) $49.20
  • Low(U.S.) $47.64
  • Bid / Ask(U.S.) $46.58 / (U.S.) $51.22
  • YTD % change-17.51%
  • Volume4,292,189
  • Average volume (10-day)2,029,126
  • Average volume (1-month)1,463,374
  • Average volume (3-month)1,476,151
  • 52-week range(U.S.) $42.41 to (U.S.) $60.34
  • Beta0.87
  • Trailing P/E23.65×
  • P/E 1 year forward20.61×
  • Forward PEG1.79×
  • Indicated annual dividend(U.S.) $0.76
  • Dividend yield1.59%
  • Trailing EPS(U.S.) $2.03
Updated February 10 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+32.30%

Based on its net profit margin of 32.30%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.79%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue28,87626,79227,05925,200
Total other revenue--------
Total revenue28,87626,79227,05925,200
Gross profit24,26822,94523,20021,326
Total cost of revenue4,6083,8473,8593,874
Total operating expense17,75114,81214,57711,343
Selling / general / administrative9,2037,9038,0627,001
Research & development4,0343,2893,0353,250
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--00-2,376
Other operating expenses, total-94-227-379-406
Operating income11,12511,98012,48213,857
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax10,31410,13610,54812,485
Income after tax8,2588,3838,3439,876
Income tax, total2,0561,7532,2052,609
Net income8,2588,3838,3439,876
Total adjustments to net income--------
Net income before extra. items8,2588,3838,3439,876
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items8,2588,3838,3439,876
Inc. avail. to common incl. extra. items8,2588,3838,3439,876
Diluted net income8,2588,3848,3439,876
Dilution adjustment01----
Diluted weighted average shares2,5602,5722,5842,604
Diluted EPS excluding extraordinary itemsvalue per share3.233.263.233.79
Dividends per sharevalue per share5.220.000.000.00
Diluted normalized EPSvalue per share3.233.263.233.07